Overview

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Status:
Completed

Trial end date:
2013-09-24

Target enrollment:

Participant gender:

Summary

The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Muscarinic Antagonists
Tiotropium Bromide